Leggett & Platt, Incorporated designs, manufactures, and sells engineered components and products in the United States, Europe, China, Canada, Mexico, and internationally. The company offers steel rod, drawn wire, innersprings, specialty foam chemicals and additives, for use in bedding and furniture, semi-finished mattresses, private label finished mattresses, pillows and toppers, static foundations, adjustable beds, machines to produce innersprings, industrial sewing and quilting machines, and mattress-packaging and glue-drying equipment to industrial users of steel rod and wire, manufacturers of finished bedding, bedding brands and mattress retailers, e-commerce retailers, big box retailers, department stores, and home improvement centers. It also provides mechanical and pneumatic lumbar support and massage systems for automotive seating, seat suspension systems, motors and actuators, and cables; titanium, nickel, and stainless-steel tubing, formed tubes, tube assemblies, and flexible joint components for fluid conveyance systems; and engineered hydraulic cylinders to automobile original equipment manufacturers (OEMs) and suppliers, aerospace OEMs and suppliers, and mobile equipment OEMs. In addition, the company offers steel mechanisms and motion hardware; springs and seat suspensions; components and private label finished goods for soft seating; bases, columns, back rests, casters, and frames for office chairs and control devices; and carpet cushion and hard surface flooring underlayment, structural fabrics, and geo components for manufacturers of upholstered and office furniture, flooring retailers and distributors, contractors, landscapers, road construction companies, retailers, government agencies, mattress and furniture producers, and manufacturers of draperies, specialty packaging, filtration, and automotive upholstery. Leggett & Platt, Incorporated was founded in 1883 and is based in Carthage, Missouri.

Leggett & Platt Incorporated

Macquarie analyst maintained a Buy rating on Coles Group today and set a price target of A$24.10. In a report released on June 10, Morgan Stanley a...

Macquarie Reaffirms Their Buy Rating on Coles Group (CLEGF)

Legend Biotech ( ($LEGN) ) has provided an update. Legend Biotech, a leading cell therapy specialist known for its CAR-T product CARVYKTI for multi...

Legend Biotech Prices $226 Million ADS Offering to Bolster Cell Therapy Expansion

The latest announcement is out from Legend Mining Limited ( ($AU:LEG) ). Legend Mining has identified new gold-related features at its Pyrophyllite...

Legend Mining Advances Pyrophyllite Hill Gold Drill Target After New Field Results

Oppenheimer analyst Kostas Biliouris maintained a Buy rating on Legend Biotech today and set a price target of $75.00. According to TipRanks, Bilio...

Legend Biotech (LEGN) Receives a Buy from Oppenheimer

Barclays analyst Etzer Darout maintained a Buy rating on Legend Biotech today and set a price target of $80.00. Darout covers the Healthcare sector...

Barclays Keeps Their Buy Rating on Legend Biotech (LEGN)

An announcement from Legato Merger Corp. III ( ($LEGT) ) is now available. Einride AB has completed its previously announced business combination w...

Einride Completes Legato Merger and Lists on Nasdaq

In a report released on June 5, Thomas Neuhold from Kepler Capital maintained a Buy rating on LEG Immobilien, with a price target of €90.00. The co...

Kepler Capital  Remains a Buy on LEG Immobilien (0QC9)

Legato Merger Corp. III ( ($LEGT) ) just unveiled an update. On November 12, 2025, Legato Merger Corp. III entered into a Business Combination Agre...

Legato Shareholders Approve Einride Business Combination Merger

Barclays Remains a Buy on Legend Biotech (LEGN)

Legend Biotech stock was up on Tuesday alongside positive Phase 1 clinical trial data.


This Is Why Legend Biotech Stock (LEGN) Was Up Today

Legend Biotech ( ($LEGN) ) has provided an announcement. Legend Biotech said on June 2, 2026, that it will showcase initial Phase 1 data for LB2501...

Legend Biotech to Present Strong First-in-Human In Vivo CAR-T Data for LB2501 at EHA 2026

RBC Capital analyst Leonid Timashev maintained a Buy rating on Legend Biotech today and set a price target of $64.00. Timashev covers the Healthcar...

RBC Capital Remains a Buy on Legend Biotech (LEGN)

In a report released today, Kostas Biliouris from Oppenheimer reiterated a Buy rating on Legend Biotech, with a price target of $75.00. According t...

Oppenheimer Remains a Buy on Legend Biotech (LEGN)

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Legend Biotech (LEGN), Tempus AI, Inc. Class A (TE...

Analysts Offer Insights on Healthcare Companies: Legend Biotech (LEGN), Tempus AI, Inc. Class A (TEM) and Mirum Pharmaceuticals (MIRM)

In a report released today, Kai Klose from Berenberg Bank maintained a Buy rating on LEG Immobilien, with a price target of €85.00. According to Ti...

LEG Immobilien (0QC9) Gets a Buy from Berenberg Bank

In a report released today, Pierre-Emmanuel Clouard from Jefferies reiterated a Buy rating on LEG Immobilien, with a price target of €90.00. Accord...

Current Quarter	$0.29	Next Quarter	$0.28
Current Year	$0.9	Next Year	$1.03
QoQ Growth	-3.4%	YoY Growth	+14.4%
3Y EPS CAGR	-9.3%	Target Price	$11.50
Consensus	Buy	Upside	+5.3%

Current Quarter Rev	N/A	Next Quarter Rev	N/A
Revenue Growth	N/A	YoY Growth	N/A

	A	B	C	D
1	Symbol	Price	Change	Volume
2	LEG	$10.92	+2.44%	2.60M
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	LEG	$10.92	+2.4%	2.60M
3
4
5
6

LEG

LEG

EPS Estimates Overview

EPS Historical Trend (5 Years)

Quarterly EPS Estimates

Revenue Analysis

Get Leggett & Platt Incorporated Data in Excel

Get Leggett & Platt Incorporated Data in Excel